At diagnosis, all patients with MTC should be screened for rearranged during transfection (RET) mutations due to the fact that 20%–25% of cases have germline mutation being part of multiple endocrine neoplasia type 2 syndrome (MEN2) (1, 2). The gene discussed is RET; the disease is medullary thyroid gland carcinoma.